Development of a severity scale to assess chronic lung disease after extremely preterm birth.


Journal

Pediatric pulmonology
ISSN: 1099-0496
Titre abrégé: Pediatr Pulmonol
Pays: United States
ID NLM: 8510590

Informations de publication

Date de publication:
06 2021
Historique:
revised: 23 12 2020
received: 21 10 2020
accepted: 07 01 2021
pubmed: 18 3 2021
medline: 25 11 2021
entrez: 17 3 2021
Statut: ppublish

Résumé

Chronic lung disease of prematurity (CLDP) is a frequent complication of prematurity. We aimed to identify what clinicians believe are the most important factors determining the severity of CLDP in extremely preterm infants (<28 weeks gestational age) after discharge from the neonatal intensive care unit (NICU) through 12 months corrected age (CA), and to evaluate how these factors should be weighted for scoring, to develop a CLDP severity scale. Clinicians completed a three-round online survey utilizing Delphi methodology. Clinicians rated the importance of various factors used to evaluate the severity of CLDP, from 0 (not at all important) to 10 (very important) for the period between discharge home from the NICU and 12 months CA. Fourteen factors were considered in Round 1; 13 in Rounds 2 and 3. The relative importance of factors was explored via a set of 16 single-profile tasks (i.e., hypothetical patient profiles with varying CLDP severity levels). Overall, 91 clinicians from 11 countries who were experienced in treating prematurity-related lung diseases completed Round 1; 88 completed Rounds 2 and 3. Based on Round 3, the most important factors in determining CLDP severity were mechanical ventilation (mean absolute importance rating, 8.89), supplemental oxygen ≥2 L/min (8.49), rehospitalizations (7.65), and supplemental oxygen <2 L/min (7.56). Single-profile tasks showed that supplemental oxygen had the greatest impact on profile classification. The most important factors for clinicians assigning CLDP severity during infancy were mechanical ventilation, supplemental oxygen ≥2 L/min, and respiratory-related rehospitalizations.

Identifiants

pubmed: 33729710
doi: 10.1002/ppul.25279
pmc: PMC8251957
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1583-1592

Informations de copyright

© 2021 The Authors. Pediatric Pulmonology Published by Wiley Periodicals LLC.

Références

Clin Perinatol. 2019 Jun;46(2):291-310
pubmed: 31010561
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1398-1406
pubmed: 31995403
J Pediatr. 2017 Sep;188:24-34.e1
pubmed: 28645441
Am J Respir Crit Care Med. 2019 Sep 15;200(6):751-759
pubmed: 30995069
Pediatrics. 2010 Sep;126(3):443-56
pubmed: 20732945
J Matern Fetal Neonatal Med. 2021 Jun;34(11):1721-1731
pubmed: 31397199
N Engl J Med. 2007 Nov 8;357(19):1946-55
pubmed: 17989387
Front Pediatr. 2019 Dec 12;7:510
pubmed: 31921723
J Pediatr. 2017 Aug;187:89-97.e3
pubmed: 28528221
J Pediatr. 2019 Mar;206:56-65.e8
pubmed: 30471715
Value Health. 2013 Jan-Feb;16(1):3-13
pubmed: 23337210
Am J Respir Crit Care Med. 2001 Jun;163(7):1723-9
pubmed: 11401896
J Pediatr. 2018 Jun;197:300-308
pubmed: 29551318
Pediatr Pulmonol. 2015 Sep;50(9):878-88
pubmed: 25651820
J Neonatal Perinatal Med. 2018;11(2):121-130
pubmed: 29843269
J Pediatr. 2018 Dec;203:218-224.e3
pubmed: 30172426
Pediatr Pulmonol. 2021 Jun;56(6):1583-1592
pubmed: 33729710
J Pediatr. 2004 Jun;144(6):799-803
pubmed: 15192629
JAMA Pediatr. 2015 Feb;169(2):e143676
pubmed: 25642906

Auteurs

Hugh M O'Brodovich (HM)

Department of Pediatrics, Stanford University School of Medicine, Stanford, California, USA.

Robin Steinhorn (R)

Department of Pediatrics, University of California San Diego, San Diego, California, USA.

Robert M Ward (RM)

Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA.

Mikko Hallman (M)

Oulu University Hospital, University of Oulu, Oulu, Finland.

Ethan J Schwartz (EJ)

Patient Centered Outcomes, ICON, Gaithersburg, Maryland, USA.

Magdalena Vanya (M)

Patient Centered Outcomes, ICON, South San Francisco, California, USA.

Ellen M Janssen (EM)

Patient Centered Outcomes, ICON, Gaithersburg, Maryland, USA.

Alexandra Mangili (A)

Global Clinical Development, Rare Metabolic Diseases, Takeda, Zurich, Switzerland.

Linda Han (L)

Global Clinical Development, Rare Metabolic Diseases, Takeda, Cambridge, Massachusetts, USA.

Sujata P Sarda (SP)

Global Evidence and Outcomes, Takeda, Lexington, Massachusetts, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH